ImCheck Therapeutics finalised its Series B fundraising for a total amount of €48 million, enabling them to advance its clinical pipeline of antibodies targeting gamma delta T cells against cancer and autoimmune diseases; Dechert, Dentons and Plasseraud IP advised as part of the operation
Dechert advised new investors (including InnoBio, Bpifrance Participations, Capital Agent, Wellington Partners Venture Capital and Alexandria Venture Investments); Dentons advised the Marseille biotechnology company, Imcheck Therapeutics, its founders and historical investors (Boehringer Ingelheim Venture Fund (BIVF), Kurma Partners, Idinvest, Gimv and LSP); and, Alexandra Carrel from Cabinet Carrel and Denis Bourgarel CPI from Plasseraud IP advised ImCheck on intellectual property aspects.
